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TheEpstein–Barr virus (EBV) is an oncogenic humangamma-herpesvirus that predominantly
establishes latent infection in B lymphocytes. Viral genomes exist as extrachromosomal
episomes with a nucleosomal structure. Maintenance of virus latency or execution of
reactivation is controlled by the expression of BZLF1, a viral immediate-early gene
product, tightly controlled at the transcriptional level. In this article, we review how BZLF1
transcription is controlled, in other words how virus reactivation is regulated, especially
in terms of epigenetics. We recently found that histone H3 lysine 27 trimethylation
(H3K27me3) and H4K20me3 markers are crucial for suppression of BZLF1 in latent Raji
cells. In addition, H3K9me2/3, heterochromatin protein 1, and H2A ubiquitination are
associated with latency, whereas positive markers, such as higher histone acetylation
and H3K4me3, are concomitant with reactivation. Since lytic replication eventually causes
cell cycle arrest and cell death, development of oncolytic therapy for EBV-positive cancers
is conceivable using epigenetic disruptors. In addition, we note the difﬁculties in analyzing
roles of epigenetics in EBV, including issues like cell type dependence and virus copy
numbers.
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INTRODUCTION
The Epstein–Barr virus (EBV), a human gamma-herpesvirus that
predominantly establishes latent infection in B lymphocytes, is
associated with various disease entities, including Burkitt’s lym-
phoma, post-transplant lymphoproliferative disorder (PTLD),
Hodgkin’s disease, gastric cancer, and nasopharyngeal carcinoma
(NPC). Only a small percentage of infected cells switch from the
latent stage into the lytic cycle and produce progeny viruses. Tran-
sitions and differences in EBV infection cycling between lytic and
latent states are closely tied, not only with the virus production
and spread, but also with disease progression and malignancy
of EBV-positive cancers, and thus detailed analysis of molecu-
lar mechanisms that govern the EBV latent-to-lytic switch is of
fundamental importance.
LATENCY AND REACTIVATION OF EBV IS REGULATED BY AN
ABUNDANCE OF BZLF1
Although the mechanism of EBV reactivation in vivo is not
fully understood, it is known to be elicited in vitro by treat-
ment of latently infected B cells with some chemical or biological
reagents, such as 12-O-tetradecanoylphorbol-13-acetate (TPA),
calcium ionophores, sodium butyrate, and anti-immunoglobulin
(Ig). Stimulation of the EBV lytic cascade by these reagents leads
to expression of two viral immediate-early genes, BZLF1 (also
known as Zta, EB1, ZEBRA, or Z) and BRLF1 (Rta or R). The
BZLF1 protein is a transcriptional activator that shares structural
similarities to basic leucine zipper (b-Zip) family transcriptional
factors and BZLF1 expression alone can trigger the entire reac-
tivation cascade (Speck et al., 1997; Amon and Farrell, 2005;
Tsurumi et al., 2005). BZLF1 has a very interesting and unique
characteristic trial. In cells latently infectedwith EBV, the viral lytic
promoters are strongly repressed by repressive epigenetic marks,
including heavy 5′-CG-3′ dinucleotide (CpG) DNA methylation
(Fernandez et al., 2009), but BZLF1 can preferentially bind to and
activate the methylated promoters (Bhende et al., 2004; Dicker-
son et al., 2009; Flower et al., 2011). Therefore, BZLF1 serves as
the molecular switch for EBV reactivation from latency. Actually,
induction of BZLF1 (20- to 50-folds) by anti-IgG or other chemi-
cal inducers (seeFigure 1) can cause efﬁcient viral gene expression,
viral DNA replication and progeny production, at least in Akata
or B95-8.
POSITIVE/NEGATIVE CONTROL OF BZLF1 EXPRESSION BY
TRANSCRIPTION FACTORS
Expression of the BZLF1 gene is tightly controlled at the tran-
scriptional level. The BZLF1 promoter (Zp) normally exhibits low
basal activity and is activated in response to TPA or the other
reagents listed above. The promoter is activated by transcriptional
factors including myocyte enhancer factor 2 (MEF2; Liu et al.,
1997b) and Sp1/3 (Liu et al., 1997a). Cellular b-Zip type transcrip-
tion factors, such as the cyclic AMP-response element-binding
protein (CREB), activating transcription factor (ATF), activator
protein-1 (AP-1; Ruf and Rawlins, 1995; Liu et al., 1998; Murata
et al., 2009, 2011) or a spliced form of the X-box binding pro-
tein 1 [XBP-1(s); Bhende et al., 2007], also play crucial roles in
the promoter activation.We previously showed the importance of
CREB and its calcineurin-dependent activation by transducer of
regulated CREB 2 (TORC2; Murata et al., 2009). Once produced,
BZLF1 itself can bind to and activate its own promoter (Flem-
ington and Speck, 1990; Murata et al., 2010). Most of the positive
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FIGURE 1 | Effects of an HDAC inhibitorTSA on BZLF1 expression differ
with the type of EBV-positive cell. Akata, Raji, B95-8, and GTC-4 cells
were treated with either vehicle (Cont) or 300 nMTSA. Anti-IgG (for Akata)
or TPA/A23187/butyrate (for B95-8, Raji, and GTC-4) served as positive
controls, as these substances induce BZLF1. After 24 h, RNAs were
collected and real-time RT-PCR was carried out to measure the levels of
BZLF1 mRNA, the results being shown as bars after normalization to levels
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. TSA alone
treatment induced BZLF1 expression in Akata, but did not appreciably
enhance in other cells.
factors have been demonstrated or are presumed to up-regulate
the BZLF1 promoter by recruiting transcriptional coactivators,
such as histone acetylases. On the other hand, the activity of Zp
is restricted by repressive factors including Jun dimerization pro-
tein 2 (JDP2; Murata et al., 2011), zinc ﬁnger E-box binding factor
(ZEB; Yu et al., 2007), Yin Yang 1 (YY1; Montalvo et al., 1995),
and an unidentiﬁed repressor that binds to the ZIIR motif (Liu
et al., 1998).
EPIGENETICS OF THE BZLF1 PROMOTER ASSOCIATED WITH
LATENCY AND REACTIVATION
In the previous section, we noted that BZLF1 promoter activity
is regulated positively or negatively by transcription factors and
cofactors. The question then arises of how those host transcription
factors regulate BZLF1 transcription, which eventually leads to
EBV reactivation? The answer is through epigenetic changes that
mediate transcription factors and BZLF1 expression.
With regard to epigenetics, CpG DNA methylation could be
one possible cause of BZLF1 promoter repression, as this is
frequently associated with constitutive heterochromatin, where
transcription is tightly suppressed, irreversibly. However, Fernan-
dez et al. (2009) showed that CpG methylation levels at BZLF1
promoters in various EBV-positive cell lines are exceptionally
low, although most of the viral genome in the latent phase
is highly methylated. Likewise, very little CpG DNA methy-
lation was found in the promoter region of the lytic switch
gene, ORF50/K-Rta, for Kaposi sarcoma-associated herpesvirus
(KSHV), another oncogenic gamma-herpesvirus (Gunther and
Grundhoff, 2010).
However, treatment of EBV-positive cells with 5-aza-2′-
deoxycytidine (5-Aza), a potent inhibitor of DNA methyltrans-
ferase, induces BZLF1 transcription (Murata et al., 2012; see
Figure 3). It is speculated that 5-Aza activates EBV lytic gene
expression by an unknown mechanism that does not involve
decreasedCpGDNAmethylation levels (Countryman et al., 2008).
This is because 5-Aza inducesBZLF1 expressionwithin a very short
period of time (15min or less), although it must take days to bring
about hypo-methylation of the CpG DNA, since 5-Aza is a DNA
methyltransferase inhibitor and it does not actively trim off nor
abolish methylation without de novo DNA ampliﬁcation. In fact,
accumulating data indicate that themechanismof gene inductions
by 5-Aza or its analogs is very complicated, and does not neces-
sarily depend on DNA demethylation. The inhibitors can activate
gene expressions through DNA damage (Link et al., 2008; Wang
et al., 2008), degradation of a certain proteins (Zheng et al., 2012),
or histone reorganization (Wozniak et al., 2007; Komashko and
Farnham, 2010). Therefore, it is quite likely that the consequence
of 5-Aza is a side effect, although the possibility cannot be denied
that DNAmethylation is present at Zp at least to some extent, and
plays a role in BZLF1 gene suppression (Li et al., 2012).
Possible epigenetic modiﬁcations which might silence the pro-
moter include histone changes. From a historical perspective, the
best-characterized epigenetic histone marker of BZLF1 promoter
is acetylation. Histone acetylation causes destabilization of chro-
matin, leading to a loose, open structure of the promoter, so that
it becomes easily accessible to basic transcription factors. His-
tone acetylation of EBV Zp ﬁrst came to light because histone
deacetylase (HDAC) inhibitors were found to cause reactivation
of EBV (Luka et al., 1979; Jenkins et al., 2000). Histone acetyla-
tion levels are low in latency, and are induced upon reactivation
(Murata et al., 2012). In fact, silencing of the BZLF1 promoter
in latently infected cells is mediated by and solely dependent on
low levels of histone acetylation, at least in some cell lines such as
Akata, since inhibitors of HDAC, like sodium butyrate or tricho-
statinA (TSA), can reverse the silencing (Miller et al., 2007;Murata
et al., 2012; Figure 1). However, treatment with butyrate or TSA
alone does not efﬁciently induce BZLF1 transcription in cell lines
like B95-8 or Raji, suggesting that the molecular mechanisms that
govern the suppression of BZLF1 transcription in these cells must
be more complex than simply reduction in the acetylation level
of the promoter (Countryman et al., 2008; Murata et al., 2012;
Figure 1).
In order to analyze mechanisms that govern BZLF1 tran-
scription other than histone acetylation in such a cell line,
we ﬁrst examined various epigenetic histone modiﬁcations in
the Zp of EBV DNA. Chromatin immunoprecipitation (ChIP)
assays revealed that suppressive histone markers including his-
tone H3 lysine 27 trimethylation (H3K27me3), H3K9me2/3 and
H4K20me3 are present in the Zp of latent Raji cells, while high
levels of histone acetylation and H3K4me3 markers correlate with
reactivation of the virus (Figure 2; Murata et al., 2012).
H3K27me3 is a suppressive histonemodiﬁcation, characteristic
of facultative heterochromatin, a form of heterochromatin where
expression of a wide variety of genes is considerably silenced by
speciﬁc histonemodiﬁcations (Kondo, 2009).With speciﬁc signal-
ing, histone modiﬁcations of this type of heterochromatin can be
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FIGURE 2 | Histone modification pattern of EBV BZLF1 promoter
upon lytic reactivation. Raji cells were treated with control vehicle (blue)
or TPA/A23187/butyrate (T/A/B, red) at 20 ng/ml, 1 μM and 5 mM,
respectively. ChIP experiments were performed using antibodies indicated
below, followed by real-time PCR. Active marks (H3Ac, H3K4me3) were
elevated while levels of suppressive marks (H3K27me3, H4K20me3, and
H3K9me2/3) remained unchanged.
reversed so that it becomes transcriptionally active, unlike consti-
tutive heterochromatin. The presence of H3K27me3 methylation
was recently reported by other groups in EBV Zp (Ramasub-
ramanyan et al., 2012) and KSHV ORF50/K-Rta (Gunther and
Grundhoff, 2010; Toth et al., 2010). To test if H3K27me3 modi-
ﬁcation is involved in the BZLF1 suppression during latency, we
here used an inhibitor of the modiﬁcation, 3-deazaneplanocin A
(DZNep; Tan et al., 2007; Miranda et al., 2009). While treatment
of Raji cells with either DZNep or TSA alone had only minor
effects on BZLF1 levels (1.8- and 3.3-fold increase, respectively),
use of the two inhibitors in combination (TSA + DZNep) stim-
ulated the expression 64.2-fold (Murata et al., 2012; Figure 3).
This result suggests that not only histone deacetylation but also
histone H3K27me3 serve to inhibit BZLF1 transcription, at least
in Raji cells. H3K27me3 methylation is mediated by enhancer of
zeste 2 (Ezh2), amember of polycomb repressor complex 2 (PRC2;
Cao et al., 2002). To further verify the involvement of H3K27me3
in BZLF1 gene repression, we then knocked down Ezh2. Silencing
increased BZLF1 levels by 2.5-fold evenwithout TSA, and addition
of TSA elevated this to 10.9-fold (Murata et al., 2012). Further-
more, we conﬁrmed these inhibitors and small interfering RNA
(siRNA) treatment actually caused expected changes in epigenetic
marks (see Figures 7 and 9 in Murata et al., 2012). An impor-
tance of histone H3K27me3 in the maintenance of latency was
also recently demonstrated for KSHV ORF50/K-Rta (Toth et al.,
2010). These results point to involvement of Ezh2 methyltrans-
ferase and the histone H3K27me3 marker in silencing of BZLF1
gene expression during EBV latency. In addition, we would like to
note that histone acetylation is also needed for efﬁcient expression
of BZLF1.
It has been reported that, in addition to histone H3K27me3,
H4K20me3 histone modiﬁcation is also inhibited by DZNep (Tan
FIGURE 3 | Effects of pharmacological inhibitors on BZLF1 expression
in Raji cells. Raji cells were treated with vehicle (Cont), 10 μM DZNep,
300 nMTSA, 1 μM 5-Aza alone or in combinations as indicated. As a
positive control (TPA/A/Bu), Raji cells were treated with TPA/A23187/
butyrate at 20 ng/ml, 1 μM and 5 mM, respectively. For DZNep or
5-aza-2′-deoxycytidine (5-Aza) treatment, cells were exposed to the reagent
daily for 3 days. Treatment with other chemicals was for 24 h. Real-time
RT-PCR was carried out to measure the levels of BZLF1 mRNA, which were
then normalized to GAPDH mRNA levels. The light-blue arrows indicate that
DZNep alone did not efﬁciently induce BZLF1, but could markedly enhance
the expression if treated in combination with TSA.
et al., 2007; Miranda et al., 2009), and we found H4K20me3 is
present in the Zp of latent Raji cells. In order to speciﬁcally exam-
ine the effect of the H4K20me3 methylation on silencing of the
BZLF1 gene, Suv420h1, the methyltransferase responsible for the
modiﬁcation, was knocked down by siRNA technology. Remark-
able induction of the BZLF1 gene by Suv420h1 knockdown and
TSA corresponded with reduction of H4K20me3 levels and eleva-
tion of active H3K9Ac and H3K4me3 markers (see Figures 7 and
10 in Murata et al., 2012). Therefore, we conclude that silencing
of the BZLF1 promoter in Raji cells is similarly brought about by
histone H4K20me3 methylation.
Because DZNep exhibited potent inducing effects on BZLF1
gene transcription, we also tested BIX01294, a speciﬁc inhibitor
of G9a, the methyltransferase responsible for histone H3K9me2
methylation, which is another typical marker of facultative het-
erochromatin. Paradoxically, treatment of Raji cells or other
EBV-positive cells with BIX01294 alone or in combination with
TSA, DZNep, or 5-Aza, did not increase the BZLF1 expression at
all, or caused verymodest increase atmost, even thoughH3K9me2
is present at the Zp at signiﬁcantly high level (Murata et al., 2012).
The data imply that K3K9me2 may not play an important role in
the suppression of BZLF1, at least in Raji cells.
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A representative constitutive heterochromatin marker histone
H3K9me3, too, has been reported to be deﬁnitely present during
latency in EBV Zp (Murata et al., 2012) and KSHV ORF50/K-
Rta promoters (Gunther and Grundhoff, 2010; Toth et al., 2010).
Although Toth and others observed that H3K9me3 in the KSHV
ORF50/K-Rta promoter decreased upon induction, suggesting
that the modiﬁcation is involved in silencing of the immediate-
early gene, we failed to see an equivalent decline in EBV Zp
(Murata et al., 2012; Figure 2).We speculate that this inconsistency
was related to the use of Raji cells in our experiments, since the
Raji genome has a deletion of the BALF2 gene, essential for lytic
viral DNA synthesis. Furthermore, treatment of latent Raji cells
with chaetocin, an Suv39H1 histone H3K9me3 methyltransferase
inhibitor, did not induce BZLF1 expression, even in combination
with other epigenetic inhibitors, such as TSA, DZNep, or 5-Aza.
Therefore, histone H3K9me3 modiﬁcation is a feature of EBV Zp
in latency, but we still do not have conclusive evidence that it plays
a role in the maintenance of latency, at least in Raji cells. Since
other methyltransferases, such as SETDB1/ESET, can also catalyze
histone H3K9me3 modiﬁcation, they may be acting to suppress
BZLF1 gene in the presence of chaetocin.
Histone H3K4me3 is enriched in the promoter regions of tran-
scriptionally active genes in euchromatin, and thus serves as an
active chromatin marker. It elicits transcription by recruiting
factors like chromodomain-containing and plant homeodomain
(PHD) ﬁnger proteins, as well as chromatin remodeling factors.
Lytic induction of Raji cells markedly elevated the active histone
marker, H3K4me3, in the Zp, while the level was low in latency
(Murata et al., 2012; Figure 2). Enhancement of H3K4me3 upon
induction has been reported for KSHV (Gunther and Grundhoff,
2010; Toth et al., 2010) in addition to other herpesviruses, indicat-
ing that histone H3K4me3 methylation, like histone acetylation,
plays an important and universal role in lytic gene expression of
herpesviruses.
Further to the epigenetic modiﬁcations described above,
already published by us or other groups, we have conﬁrmed
in our preliminary experiments that other epigenetic alterations
are associated with EBV latency and reactivation. In the mam-
malian genome, approximately 10% of histone H2A is mono-
ubiquitinated at Lys 119, in association with transcriptional
suppression, and then de-ubiquitinated upon transcriptional acti-
vation. We have found EBV Zp of latent Raji cells to be labeled
with high levels of mono-ubiquitinated H2A, although massive
reduction did not occur on induction. A similar ChIP result was
obtained when heterochromatin protein 1 (HP1) was monitored.
Because HP1 binds to methylated histone H3K9, the presence of
HP1 serves to strengthen signiﬁcance of H3K9 methylation at the
promoter. Thus, BZLF1 promoter has various repressive epige-
netic modiﬁcations, and also acquires cofactors associated for the
gene suppression. Physiological relevance of those factors is being
analyzed.
Interestingly, we found there is a prominent binding site of
CCCTC-binding factor (CTCF), a transcriptional regulator and
insulator, in the Zp of EBV. Binding of CTCF correlates with
binding of Rad21, a subunit of cohesion. Other groups also
recently conﬁrmed such binding to EBV Zp (Holdorf et al., 2011;
Arvey et al., 2012). Since it is known that CTCF/cohesin regulate
transcription by creating long range chromatin loops and/or by
acting as insulators, roles of such factor binding in latency and
reactivation of EBV is of great interest. Binding of CTCF/cohesin
to the KSHV ORF50/K-Rta promoter and a contribution to the
suppression of reactivation have already been established (Chen
et al., 2012), but their role in EBV reactivation may be different,
as the binding sites of CTCF/cohesin in the ORF50/K-Rta pro-
moter appear redundant while there is only one major peak of
CTCF/cohesin in the EBV BZLF1 promoter (Holdorf et al., 2011;
Arvey et al., 2012).We recently made recombinant EBVwith point
mutation at the CTCF binding site of the BZLF1 promoter, but our
preliminary data showed that disruption of CTCF binding to the
peak did not notably inﬂuence on BZLF1 levels, if any, at least in
HEK293 cells.
EPIGENETIC AGENTS AS MOLECULAR TARGETS FOR
ANTI-VIRAL/CANCER DRUGS
Because there are very limited numbers of anti-EBV drugs devel-
oped or being developed to date, including acyclic nucleoside
analogs, such as acyclovir or ganciclovir, and kinase inhibitors,
such as maribavir (Wang et al., 2009), the search and development
of effective anti-viral drugs for patients with infectious mononu-
cleosis, caused by primary and acute EBV infection in adolescence,
are important tasks. Because histone acetylation plays a crucial role
in EBV reactivation, inhibitors of histone acetyl transferase (HAT)
have potential in this regard. Inhibition of histone demethylase
LSD1 by monoamine oxidase inhibitors is reported to block alpha
herpesvirus lytic replication and reactivation from latency (Liang
et al., 2009).
Interestingly, as execution of the viral lytic program arrests
cell cycle progression in infected cells (Kudoh et al., 2003), induc-
tion of EBV lytic replication in EBV-positive cancers by epigenetic
inhibitors, such as HDAC inhibitors, 5-Aza, and/or DZNep, may
offer clinical application as a type of oncolytic therapy in the
future (Feng et al., 2004; Jung et al., 2007). Because treatment
like this must induce efﬁcient production of progeny viruses,
anti-viral drugs, such as ganciclovir, should obviously be used
in combination to both induce apoptosis and prevent viral
spreading.
PARTICULARITY AND DIFFICULTIES OF ANALYZING EBV
EPIGENETICS
It must be emphasized that responses of BZLF1 promoter activity
to certain epigenetic inhibitors depend largely on the cell type.
To take one example, levels of BZLF1 mRNA expression in Akata
cells are markedly induced by TSA treatment alone, whereas the
virus in other cells, including B95-8 or Raji, does not appear to
respond (Murata et al., 2012; Figure 1). We have demonstrated,
in Raji cells, that BZLF1 expression is suppressed by histone
H3K27me3 andH4K20me3, in addition to low level histone acety-
lation, whilst in Akata cells, only low level histone acetylation
accounts for repression of the gene induction (Murata et al., 2012).
Curiously however, the Zp of the Akata cell line, is modiﬁed with
histone H3K27me3 and H4K20me3, almost as efﬁciently as Raji
(Murata et al., 2012). Then, why do the suppressive H3K27me3
andH4K20me3markers not actually prevent BZLF1 expression in
Akata cells?
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FIGURE 4 | Summary of epigenetic histone modifications in the BZLF1
promoter of Raji cells. Repressive histone H3K9, H3K27, H4K20
methylations (marked with blue circles) are present in latency, and are not
appreciably decreased even after induction. High levels of active markers,
such as H3K4 methylation and histone acetylation (green circles), are
notably associated with lytic induction.
Another question is why treatment with TPA, A23187, and
sodium butyrate did not affect repression markers, such as
H3K9me2/3, H3K27me3, or H4K20me3, at all in Raji, whereas
they signiﬁcantly elicited expression of BZLF1 (Murata et al.,
2012)? It is considered in general that such suppressive markers
must be diminished for transcriptional activation.
We believe these inconsistencies can be explained in terms of
latent EBV genome copy numbers. To take an example, it is known
that about 5–100 copies of the episomal EBV genome are present
per latent cell. For the ﬁrst question, let us suppose there are
10 copies of the latent EBV genome in one Akata cell, and nine
copies are modiﬁed and repressed by suppressive H3K27me3 and
H4K20me3 markers, the remaining copy being unmodiﬁed. This
means the virus inAkata cells retains high sensitivity to TSA alone.
For the secondquestion, if TPA/A23187/butyrate treatment of Raji
cells induces reduction of such repressive histone methylation in
only a few copies but still allows efﬁcient expression of BZLF1,
reduction of the repressivemodiﬁcationmust be difﬁcult to detect,
because the histone methylations in the majority of the genome
copies are intact. In contrast, induction of active histone markers,
like histone acetylation or H3K4me3 methylation, can clearly be
observed.
In addition, the presence of epigeneticmarkers, likeH3K27me3
orH3K4me3,may not in itself be sufﬁcient for suppression or acti-
vation. Adaptor or mediator complexes, such as polycomb-group
proteins or PHDﬁnger proteinsmust be recruited to the promoter
regions and appropriately act to compact or open the chromatin
structure. Therefore, we suggest that only presence or absence of a
certain epigenetic alteration in any regulatory region of EBV does
not necessarily mean that it is critical. For determination of actual
signiﬁcance, functional assays, such as use of speciﬁc inhibitors
and knockdown of epigenetic enzymes, are essential.
SUMMARY
We recently found (Murata et al., 2012) that histone H3K27me3
and H4K20me3 markers are crucial for maintenance of EBV
latency, while histone acetylation and H3K4me3 are associated
with reactivation from latency, at least in Raji cells (Figure 4).
Although there may be differences in response between cell
types, these data provide primary evidence for potential in
anti-viral/cancer drug development.
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